← Banking With Billy News

Humacyte said interim Phase 3 data showed its ATEV graft gave women on hemodialysis 91 more catheter-free days over 12 months than AV fistula. ATEV remains inve

BWB News TV • 2026-11-05 17:06 UTC • By Billy Odell Tucker-Robinson
Humacyte said interim Phase 3 data showed its ATEV graft gave women on hemodialysis 91 more catheter-free days over 12 months than AV fistula. ATEV remains inve
Humacyte said interim Phase 3 data showed its ATEV graft gave women on hemodialysis 91 more catheter-free days over 12 months than AV fistula. ATEV remains investigational and is not FDA-approved for dialysis access.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly